Preterm Delivery clinical trials at UCSF

1 research study open to eligible people

Preterm delivery is when a baby is born before 37 weeks of pregnancy. UCSF is enrolling people in a large trial that studies aspirin dose and preterm birth in about 1,800 participants. The trial is phase III, randomized, double-blind, and takes place at many hospitals.

Showing trials for

  • Aspirin Dose Escalation for the Prevention of Recurrent Preterm Delivery Trial

    open to eligible females ages 14 years and up

    This is a phase-III multi-center double-blind randomized clinical trial of 1,800 individuals with a history of prior preterm birth at less than 35 weeks gestation who are randomized to either 162 mg aspirin or 81 mg aspirin daily. The study drug will be initiated between 10 and 15 weeks gestation and continued through 36 weeks, 6 days gestation. The primary endpoint is recurrent preterm delivery or fetal death prior to 35 weeks, 0 days gestation.

    San Francisco, California and other locations

Our lead scientists for Preterm Delivery research studies include .

Last updated: